Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Summary
"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
The report comprises three sections -
Executive Summary
Landscape Updates
Pipeline Landscape
Appendix
Scope
Reasons to Buy
Summary
"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.
Key Highlights from the report -
- Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
- Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
- Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time
The report comprises three sections -
Executive Summary
- Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.
Landscape Updates
- ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
- Timeline forecasts for each approved product’s lifecycle management initiatives.
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline therapies.
Pipeline Landscape
- An overview of pipeline candidates, containing snapshots of current development status.
- Expected drug-specific events & milestones until YE 2020.
Appendix
- Current early stage RA pipeline & candidate ‘Watch List’.
- Timeline assumptions, including standard assumptions & drug-specific assumptions.
Scope
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to Buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharma’s ‘Competitor Landscape’Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Afimmune
- Akarna Therapeutics
- Akero Therapeutics
- Albireo
- Allergan
- Allergan (acquired from
- Ardelyx
- Arisaph
- AstraZeneca
- BHV Pharma Inc
- Bird Rock Bio/Janssen
- BMS
- Boehringer Ingelheim
- Can-Fite BioPharma
- Celgene
- Cempra
- Cerenis Therapeutics
- ChemomAb
- Cirius Therapeutics
- CohBar
- ConSynance Therapeutics
- CymaBay Therapeutics
- DeuteRx
- Dr. Falk Pharma GmbH
- DURECT Corporation
- Eli Lilly
- Enanta
- Galectin Therapeutics
- Galmed
- Gemcabene
- Genfit
- Gilead
- GRI Bio
- HighTide Biopharma
- Immune Pharmaceuticals Inc.
- Immuron
- Intercept
- INVENT Pharmaceuticals
- Inventiva
- Ionis Pharma-ceuticals
- Janssen
- Madrigal
- MediciNova
- Metacrine
- Mitsubishi Tanabe
- Naia
- NGM Biopharmaceuticals
- Nitto Denko
- NorthSea Therapeutics
- Novartis
- Novo Nordisk
- NuSirt BioPharma
- Oramed
- Pfizer
- Poxel
- Sanofi
- Second Genome
- Shire
- Sinew Pharma
- Sucampo Pharmaceuticals
- Synairgen
- Taiwan Pharmaceuticals
- Teva
- Tiziana Life Sciences
- Valbiotis
- Viking Therapeutics
- Virobay
- Zafgen
- Zydus Discovery
